1GA
HZNP

1st Global Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

1st Global Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-13,116
Closed -$216K – 584
2016
Q2 		$216K Buy
+13,116
New +$212K 0.03% 454

Other funds holding HZNP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

1st Global Advisors's HZNP Position: Q3 2016 in Review

1st Global Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2016, closing a stake of 13,116 shares — an estimated $216K sold.

1st Global Advisors first reported a position in HZNP in Q2 2016 and held it in 1 quarter. The position peaked at $216K in Q2 2016. 232 funds tracked by Wall St. Rank hold HZNP as of Q3 2016.

  • 1st Global Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2016 after selling out during the quarter.
  • 1st Global Advisors sold 13,116 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2016, an estimated $216K.
  • 1st Global Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2016 and held it in 1 quarter.
  • 1st Global Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $216K in Q2 2016.
  • 232 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2016.

Based on 1st Global Advisors's 13F filing for Q3 2016, filed 20 Oct 2016.